Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression
The company has an extensive IP portfolio, valid through 2040, and a drug pipeline in different preclinical and clinical stages, targeting cancer drug resistance and immune suppression. Kairos Pharma’s lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer (NCT05534646, in combination with Apalutamide) and a Phase 1 trial for EGFR-driven non-small cell lung cancer (NCT05401110, in combination with Osimertinib). The company is working with PreCheck Health Services to develop companion biomarkers for ENV-105, with the aim of…
